FY2025 EPS Estimates for Liquidia Lifted by Lifesci Capital

Liquidia Corporation (NASDAQ:LQDA) – Investment analysts at Lifesci Capital raised their FY2025 EPS estimates for Liquidia in a research note issued to investors on Monday, November 3rd. Lifesci Capital analyst C. Jubinville now forecasts that the company will earn ($0.56) per share for the year, up from their prior estimate of ($1.89). The consensus estimate for Liquidia’s current full-year earnings is ($1.51) per share. Lifesci Capital also issued estimates for Liquidia’s Q4 2025 earnings at $0.29 EPS, Q1 2026 earnings at $0.53 EPS, Q2 2026 earnings at $0.62 EPS, Q3 2026 earnings at $0.85 EPS, Q4 2026 earnings at $0.95 EPS and FY2026 earnings at $2.76 EPS.

Several other equities research analysts also recently issued reports on the company. Jefferies Financial Group reaffirmed a “buy” rating and issued a $45.00 price target on shares of Liquidia in a research report on Monday. Needham & Company LLC boosted their target price on shares of Liquidia from $36.00 to $52.00 and gave the stock a “buy” rating in a research report on Tuesday. BTIG Research reiterated a “buy” rating and set a $49.00 target price on shares of Liquidia in a research note on Tuesday. HC Wainwright raised their price target on shares of Liquidia from $35.00 to $50.00 and gave the stock a “buy” rating in a research report on Tuesday. Finally, Raymond James Financial restated a “strong-buy” rating and set a $47.00 price objective on shares of Liquidia in a report on Tuesday. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and two have assigned a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $38.56.

Liquidia Stock Performance

NASDAQ:LQDA opened at $25.60 on Thursday. The firm has a market capitalization of $2.23 billion, a PE ratio of -17.78 and a beta of 0.12. Liquidia has a 1 year low of $9.71 and a 1 year high of $29.94. The company has a current ratio of 2.20, a quick ratio of 2.41 and a debt-to-equity ratio of 6.19. The firm’s fifty day simple moving average is $24.52 and its 200 day simple moving average is $19.70.

Liquidia (NASDAQ:LQDA) last posted its earnings results on Monday, November 3rd. The company reported ($0.04) earnings per share for the quarter, beating the consensus estimate of ($0.45) by $0.41. Liquidia had a negative return on equity of 296.78% and a negative net margin of 176.04%.The company had revenue of $54.34 million for the quarter, compared to analyst estimates of $18.86 million. Liquidia’s revenue for the quarter was up 1106.7% on a year-over-year basis.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the stock. NewEdge Advisors LLC acquired a new stake in shares of Liquidia in the 2nd quarter valued at $25,000. Hurley Capital LLC bought a new position in Liquidia during the 1st quarter valued at about $32,000. GAMMA Investing LLC lifted its holdings in Liquidia by 65.6% during the 1st quarter. GAMMA Investing LLC now owns 2,961 shares of the company’s stock valued at $44,000 after purchasing an additional 1,173 shares during the last quarter. Steward Partners Investment Advisory LLC boosted its position in Liquidia by 24.0% in the second quarter. Steward Partners Investment Advisory LLC now owns 6,200 shares of the company’s stock valued at $77,000 after buying an additional 1,200 shares in the last quarter. Finally, Quarry LP bought a new stake in Liquidia during the first quarter worth about $79,000. 64.54% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Liquidia

In related news, CFO Michael Kaseta sold 11,630 shares of the company’s stock in a transaction dated Monday, October 13th. The shares were sold at an average price of $23.41, for a total value of $272,258.30. Following the sale, the chief financial officer owned 352,646 shares of the company’s stock, valued at $8,255,442.86. The trade was a 3.19% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, General Counsel Russell Schundler sold 7,839 shares of Liquidia stock in a transaction that occurred on Monday, October 13th. The shares were sold at an average price of $23.41, for a total value of $183,510.99. Following the sale, the general counsel directly owned 576,017 shares in the company, valued at $13,484,557.97. The trade was a 1.34% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 849,141 shares of company stock worth $23,584,920 in the last 90 days. 26.50% of the stock is currently owned by insiders.

Liquidia Company Profile

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).